Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

By Goodin Douglas S.   Biermann Louis D.   Bohlega Saeed   Boiko Alexey   Chofflon Michel   Gebeily Souheil   Gouider Riadh   Havrdova Eva   Jakab Gabor   Karabudak Rana   Karussis Dimitrios   Miller Ariel   Pakdaman Hossein   Selmaj Krzysztof   Sharief Mohammad    

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2823-2832

Informa Healthcare

Access to resources Recommend Favorite

Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

By Bailey B.  

Irish Journal of Medical Science, Vol. 180, Iss. 2, 2011-06 ,pp. : 337-341

Springer Publishing Company

Access to resources Recommend Favorite

Disease‐modifying treatments for multiple sclerosis – a review of approved medications

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 23, Iss. S1, 2016-01 ,pp. : 18-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

By Hutchinson Michael   Fox Robert J.   Havrdova Eva   Kurukulasuriya Nuwan C.   Sarda Sujata P.   Agarwal Sonalee   Siddiqui Mohd Kashif   Taneja Ankush   Deniz Baris  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 613-627

Informa Healthcare

Access to resources Recommend Favorite

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs*

By Birnbaum Howard G.   Ivanova Jasmina I.   Samuels Seth   Davis Matthew   Cremieux Pierre Y.   Phillips Amy L.   Meletiche Dennis  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 869-877

Informa Healthcare

Access to resources Recommend Favorite